VCEL - Vericel inks contract for new cell therapy manufacturing facility headquarters

Vericel Corporation (NASDAQ:VCEL) entered into a long-term lease agreement for a new state-of-the-art advanced cell therapy manufacturing and corporate headquarters facility at the Network Drive campus at Northwest Park in Burlington, Massachusetts. The company said the new facility will increase its cell therapy manufacturing capacity to support the long-term growth of MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The facility is expected to be completed in 2024, with commercial manufacturing expected to begin in 2025.

For further details see:

Vericel inks contract for new cell therapy manufacturing facility, headquarters